Pressure
BioSciences
Unveils
Aggressive
Growth
Plan and Goals
for
Second Half 2021;Company
Marches Toward UST
Commercial Release, Up-listing,
and
Profitability
Company's
Strong
First
Half
2021
Viewed
as
Launch Pad
for
Accelerating
Second
Half and
Growth
Trajectory,
Propelled by Multiple
Platform
Technologies
Building Market Traction
South
Easton, MA, August
5,
2021 -- InvestorsHub
NewsWire -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the
development and sale of broadly enabling, pressure-based
instruments, consumables, and platform technology solutions
to the
worldwide
biotechnology,
biotherapeutics, nutraceuticals,
cosmetics,
agriculture, and
food
&
beverage
industries, today
announced major
aggressive
goals for the second half
of 2021. The Company believes
these goals are attainable by the end of the
year, and that once
achieved, the Company
will be
on a rapid path to growth,
profitability,
and
success.
Mr.
Richard T. Schumacher, President and CEO of PBI,
commented:
"We have
enjoyed
a very
exciting and successful first half
of 2021. As strong
as
this
first half was,
we believe the second
half 2021
will
be
even
stronger,
in both
financial and
operational results.
We are
specifically excited about our key
goals
to close
on the Agrochem asset purchase,
to
completely clean up our Balance Sheet (as we convert debt to
equity), to
commercially
release
our
UST-based nanoemulsions
platform
technology,
and to
complete our up-list, all by the end of 2021. These
are very exciting times for all stakeholders in
PBIO."
The
Company defined
nine
areas in
which PBI made excellent
progress through
the
First
Half
2021
("FH21"),
and announced specific goals for each area for the
Second
Half
2021 ("SH21"):
Strengthen
Financial Position
-
FH21
Achievements:
Initiated
Balance
Sheet Restructuring. Reported
Initial Conversions of Debt
to Equity.
-
SH21
Goals:
Complete Balance Sheet Restructuring with
Payoffs
and
Conversions of All
Loan
Debt to
Equity.
Revenue,
Operating Income
-
FH21
Achievements:
Reported
Strong Q1 (Highest Revenue and Second
Lowest
Operating Loss since
2018).
Company
has Offered
Guidance
for an
Even Stronger Q2.
-
SH21
Goals:
Report Our First Ever Million Dollar Quarter During the Second Half
of 2021. Continue
to Reduce Operating
Loss.
Up-list
to NASDAQ or NYSE
-
FH21
Achievement:
Developed Plan to Meet Requirements of NASDAQ or NYSE to Qualify
for 2021 Listing.
-
SH21
Goal:
Trade on the NASDAQ or
NYSE
Prior to December 31, 2021.
Acquisition
of Eco-Friendly Agrochem Company
-
FH21
Achievements:
Completed Due Diligence, Executed LOI, Launched Integration
Planning, and Formed PBI Agrochem -
a PBI Wholly Owned Subsidiary for the New Agrochem
Asset.
-
SH21
Goals:
Close Acquisition and
Book
Initial $1M
Agrochem
Revenue
in Q3.
Goal
of $2.5M
Revenue in Second Half of
2021. Set Stage for
Significant Revenue Growth
in
2022 and
Beyond.
Expansion
of Intellectual Property Estate
-
FH21
Achievements:
Awarded
Three New
Ultra Shear Technology™ (UST™) Patents. Important Trade
Secret Intellectual Property
Developed to Further Protect and
Support
Commercialization
of UST-Based
Nanoemulsions.
-
SH21
Goals:
Expect Additional UST, BaroFold, and PCT Patent Awards
(Currently
Have
Total
of 29
Issued
Patents).
Continue
to File New UST and
BaroFold Provisional Patents.
Partnership
with Ohio State University
-
FH21
Achievements: Formed
Food Industry Consortium with OSU for Proven
Successful Evaluation-to-License
Model to be Applied for Rapid Adoption of UST Nanoemulsions
Platform Technology through Major
and
Other Food/Beverage
Companies Worldwide.
-
SH21
Goals:
Set Up Industrial Scale UST Prototype at OSU Demo Lab
and
Launch Evaluation-to-License
Program for Consortium Members. Sign at Least
Two Significant
Food/Beverage License
Agreements.
Ultra
Shear Technology (UST) Platform
-
FH21
Achievements:
Announced
UST-based Nanoemulsions Soared Past One-Year Stability
Goals.
Reported
on
UST-Processed
High
Quality Nanoemulsions
of CBD
and Astaxanthin (Highest Potency
Antioxidant Known).
-
SH21
Goals:
Execute Multi-Year
License
Deals with at Least Two of the CBD, Astaxanthin, Prednisone,
Retinol, etc. Nutraceutical
Companies
Currently
Engaged
in
Negotiations.
BaroFold
Platform
-
FH21
Achievements:
Doubled
Size of Client
Base, including
Addition
of Multi-Billion Dollar
Asian Pharma Client and a
Well-Financed U.S.
BioPharma.
-
SH21
Goals:
Advance
at Least
One Client into
PBI's
2nd
Stage of
Partnership, for Increased
Production Scale Supporting Investigational New Drug Application to
FDA and Closing
in on Commercialization and
Royalty Payments to PBI.
Pressure
Cycling Technology (PCT) Platform
-
FH21
Achievements:
Advanced
Implementation Planning for Co-Marketing
Agreement around PCT Integration with Leica
Microsystems Laser
Micro-Dissection Automated Platform, Highlighting
Dr.
Thomas
Conrad's
Novel PCT Cancer Biopsy Workflow Developed at INOVA
Schar Cancer Institute.
-
SH21
Goals:
Unveil and Support the Leica-PBI Collaborative Workflow Based on
Dr. Conrad's Stunning Revelation
of Diagnosis/Prognosis Changing Cancer Biopsy
Data Results.
Mr.
Jeffrey N. Peterson, PBI's Board
Chairman, provided a broader
context: "Our
team has
capitalized smartly on the momentum of our strong results,
announced growth and accretive acquisition planning, and increasing
investor support to achieve terrific progress in resolving debt and
accrued expense balances and consequent strengthening of our
balance sheet. All of this is in preparation for completion
of our announced agrochemical company assets acquisition, a new
trajectory of accretive growth, and a rapid progression to
completion of our long-planned NASDAQ or NYSE up-listing. We are
grateful to our investors for their steadfast support through
challenging periods and are excited to be sharing our
belief
for
completion of a rapid transition into
profitability in 2022."
About
Pressure
BioSciences,
Inc.
Pressure
BioSciences,
Inc.
(OTCQB:
PBIO)
is
a
leader
in
the
development
and
sale
of
innovative,
broadly
enabling,
pressure-based
solutions
for
the
worldwide
life
sciences
and
other
industries.
Our
products
are
based
on
the
unique
properties
of
both
constant
(i.e.,
static)
and
alternating
(i.e.,
pressure
cycling
technology,
or
PCT)
hydrostatic
pressure.
PCT
is a
patented
enabling
technology
platform
that
uses
alternating
cycles
of hydrostatic
pressure
between
ambient
and
ultra-high
levels
to control
bio-molecular
interactions
safely
and
reproducibly
(e.g.,
cell
lysis,
biomolecule
extraction).
Our
primary
focus
is
in
the
development
of PCT-based
products
for
biomarker
and
target
discovery,
drug
design
and
development,
biotherapeutics
characterization
and
quality
control,
soil
&
plant
biology,
forensics,
and
counter-bioterror
applications.
Additionally,
major
new
market
opportunities
have
emerged
in
the
use
of
our
pressure-based
technologies
in
the
following
areas:
(1)
the
use
of our
recently
acquired,
patented
technology
from
BaroFold,
Inc.
(the
"BaroFold"
technology)
to
allow
entry
into
the
bio-pharma
contract
services
sector,
and
(2)
the
use
of our
recently-patented,
scalable,
high-efficiency,
pressure-based
Ultra
Shear
Technology
("UST")
platform
to
(i)
create
stable
nanoemulsions
of otherwise
immiscible
fluids
(e.g.,
oils
and
water)
and
to
(ii)
prepare
higher
quality,
homogenized,
extended
shelf-life
or room
temperature
stable
low-acid
liquid
foods
that
cannot
be
effectively
preserved
using
existing
non-thermal
technologies.
Forward
Looking
Statements
This
press
release
contains
forward-looking
statements.
These
statements
relate
to future
events
or
our
future
financial
performance
and
involve
known
and
unknown
risks,
uncertainties
and
other
factors
that
may
cause
our
or
our
industry's
actual
results,
levels
of
activity,
performance,
or
achievements
to
be
materially
different
from
any
future
results,
levels
of activity,
performance
or
achievements
expressed,
implied,
or inferred
by these
forward-looking
statements.
In some
cases,
you can
identify
forward-looking
statements
by
terminology
such
as
"may,"
"will,"
"should,"
"could,"
"would,"
"expects,"
"plans,"
"intends,"
"anticipates,"
"believes,"
estimates,"
"predicts,"
"projects,"
"potential"
or "continue"
or the
negative
of
such
terms
and
other
comparable
terminology.
These
statements
are
only
predictions
based
on
our
current
expectations
and projections
about
future
events.
You
should
not
place
undue
reliance
on
these
statements.
In evaluating
these
statements,
you
should
specifically
consider
various
factors.
Actual
events
or results
may
differ
materially.
These
and
other
factors
may cause
our actual
results
to
differ
materially
from
any
forward-looking
statement.
These
risks,
uncertainties,
and
other
factors
include,
but
are
not
limited
to,
the
risks
and
uncertainties
discussed
under
the
heading
"Risk
Factors"
in
the
Company's
Annual
Report
on
Form
10-K
for
the
year
ended
December
31,
2020, and
other
reports
filed
by
the
Company
from
time
to
time
with
the
SEC.
The
Company
undertakes
no
obligation
to
update
any
of the
information
included
in this
release,
except
as
otherwise
required
by law.
For
more
information
about
PBI
and
this
press
release,
please
click
on
the following
website
link:
http://www.pressurebiosciences.com
Please
visit
us
on
Facebook,
LinkedIn,
and
Twitter.
Pressure Biosciences (CE) (USOTC:PBIO)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Pressure Biosciences (CE) (USOTC:PBIO)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
